Navigation Links
bioLytical to Present Findings of Early HIV Detection
Date:7/7/2015

bioLytical Laboratories Inc. announced today that its abstract highlighting early HIV detection using INSTI HIV-1/HIV-2 Antibody Test was accepted for presentation at the 8th Annual International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver. The results will be presented Wednesday, July 22nd from 1:00 pm to 2:00pm Pacific Standard Time at the poster discussion on Novel Programmatic Approaches for Diagnostics.

bioLytical is pleased to be selected by IAS from many reputable abstract submissions and is looking forward to showcasing its new data at this internationally renowned conference. The conference will provide new insights into HIV disease development, prevention and treatment where approximately 6,000 delegates from across the globe will be in attendance.

The treatment as prevention (TasP) strategy established by Vancouver-based researcher, Dr. Julio Montaner, was first adopted by healthcare agencies in British Columbia (B.C.) and has shown impressive results that have rippled through the global HIV/AIDS community. By 2012, B.C.’s rate of new HIV diagnoses had decreased to their lowest point ever. With the recent adoption by the United Nations of the TasP strategy and the ambitious 90-90-90 target, Vancouver has become the perfect back drop to showcase innovations to the global scientific community.

“INSTI HIV-1/HIV-2 Antibody Test has been a recommended tool for HIV detection in all healthcare settings due to its quick, accurate results. Previously, studies have proven INSTI’s performance in early detection but bioLytical’s scientists have replicated and pinpointed this connection to IgM. The Company is delighted to have the opportunity to share these findings this month and looks forward to connecting with many key opinion leaders this year at the world-renowned IAS Conference.” said Rick Galli, Chief Technical Officer of bioLytical Laboratories.

In addition, the Company is equally pleased to announce its INSTI HIV-1/HIV-2 Antibody test will also be featured in two separate poster discussions at IAS 2015. The two poster discussion presentations (Abstract #WEPDD0106, Room 118-120 and Abstract #A-729-0097-02698, Room 121-122) titled “Sensitivity of a rapid point of care assay for early HIV antibody detection is enhanced by its affinity for HIV gp41 IgM antibodies” and "Reliability of rapid HIV-1/HIV-2 INSTI on plasma and capillary blood for diagnosis of non B subtypes and circulating recombinant forms of HIV-1 circulating in Gabon,” will be available on the bioLytical website at http://www.biolytical.com following the conference.

About bioLytical Laboratories
bioLytical Laboratories is a privately owned Canadian company engaged in the research, development and commercialization of rapid, point-of-care in vitro medical diagnostics using its proprietary INSTI™ technology platform. Today, the company markets and sells its signature INSTI™ HIV test and has a world-wide footprint of regulatory approvals including U.S. FDA approval, Health Canada approval and CE mark from European regulators. Their product provides a highly accurate HIV test result in as little as 60 seconds translating into a compelling value proposition for patients, healthcare professionals and public health organizations. For more information on bioLytical Laboratories, please visit http://www.biolytical.com.

Read the full story at http://www.prweb.com/releases/2015/07/prweb12833134.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. bioLytical Partners with Walgreens and Donates HIV Tests for National HIV Testing Day
2. bioLytical Laboratories Grants Exclusive Global License for 60 Second Ebola Assay
3. bioLyticals INSTI HIV Assay Receives FDA Approval for HIV-2
4. Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA
5. Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015
6. Pharnexts PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting
7. PDL BioPharma to Present at the Nasdaq 32nd Investor Program
8. Organovo Holdings, Inc. To Present at Cantor Fitzgerald Inaugural Healthcare Conference
9. Progyny to Present at the 2015 JMP Securities Life Science Conference
10. Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
11. Twist Bioscience To Present At The 2015 JMP Securities Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2018)... , ... July 25, 2018 , ... ... research utilizing its state-of-the-art Digital Vivarium™ and Vium Cloud approach to accelerate preclinical ... Chief Scientific Officer. Additionally, the company announced the appointment of Jeff Caron to ...
(Date:7/25/2018)... ... July 25, 2018 , ... ... Systems Innovator, joined the board of the Indiana India Business Council (IIBC), an ... elected today by the current board of directors, McDonald joins an impressive roster ...
(Date:7/24/2018)... ... July 24, 2018 , ... Boval was founded in 1978 ... reagent suppliers. In Boval’s early days most of the BSA manufactured was for ... BSA for diagnostic purposes after gel cards changed that market and displaced most of ...
(Date:7/22/2018)... ... July 19, 2018 , ... Mitotech ... with Essex Bio-Investment for Phase 3 clinical program in Dry Eye Disease. Under ... SkQ1 with approximately $17m allocated towards the first Phase 3 study starting as ...
Breaking Biology Technology:
(Date:8/9/2018)... ... August 08, 2018 , ... Plum Alley Investments, an innovative ... healthcare companies, has invested in a sought-after $23 million Series A round for ... and Mammoth Biosciences , The biotech company is bringing to market the latest ...
(Date:8/7/2018)... SAN DIEGO (PRWEB) , ... August 07, 2018 ... ... biosensors that accelerate pharmaceutical and biotherapeutics development, announces a new publication titled, ... journal Bioorganic & Medicinal Chemistry. The paper prominently features use of Agile R100, ...
(Date:8/1/2018)... ... , ... Dr. Asher Kimchi, Founder and Chairman of the International Academy ... at the 23rd World Congress on Heart Disease held in Boston, MA, USA. In ... Distinguished Fellowship Awards. , Dr. Asher Kimchi, together with Chairman Dr. John A. Elefteriades, ...
Breaking Biology News(10 mins):